Lyell Immunopharma to Present at Baird Healthcare Conference
Event summary
- Lyell Immunopharma to participate in Baird 2026 Global Healthcare Conference on September 15, 2026.
- Fireside chat scheduled for 2:00 pm Eastern Time.
- Live webcast available via Lyell’s Investors section.
- LyFE Manufacturing Center™ expected to produce over 1,200 CAR T-cell doses annually.
The big picture
Lyell’s participation in the Baird conference underscores its push to engage investors as it advances late-stage CAR T-cell therapies. The focus on manufacturing capacity highlights the operational challenges in scaling cell therapies, a critical factor in the biotech sector. Lyell’s ability to deliver durable clinical responses will determine its long-term market positioning.
What we're watching
- Clinical Progress
- How Lyell’s next-generation CAR T-cell therapies perform in late-stage trials.
- Manufacturing Scale
- Whether Lyell’s LyFE Manufacturing Center™ can sustain commercial production demands.
- Market Positioning
- The pace at which Lyell differentiates itself in the competitive CAR T-cell therapy space.